[1] | WHO | Out-of-pocket payments, user fees and catastrophic expenditure. WHO. 2018. |
[2] | Pendrith C, Thind A, Zaric GS, Sarma S. Costs of cervical cancer treatment: Population-based estimates from Ontario. Curr Oncol. 2016; 23(2): e109–15. |
[3] | Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet]. 2018 Sep 12 [cited 2018 Nov 7]; Available from: http://doi.wiley.com/10.3322/caac.21492. |
[4] | Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24(SUPPL. 3). |
[5] | WHO | Key statistics. WHO [Internet]. 2012 [cited 2018 Nov 7]; Available from: http://www.who.int/cancer/resources/keyfacts/en/. |
[6] | ICO. Kenya: Human papillomavirus and related cancers, fact sheet 2017 (ICO Information Centre on HPV and Cancer). 2017 [cited 2018 Mar 21]; 2. Available from: http://www.hpvcentre.net/statistics/reports/KEN_FS.pdf. |
[7] | Strategies for Overcoming the Barriers to Cervical Cancer Screening in Low-Resource Settings. Glob Libr Women’s Med. 2009. |
[8] | Fiander AN. The prevention of cervical cancer in Africa. Vol. 7, Women’s Health. SAGE PublicationsSage UK: London, England; 2011. p. 121–32. |
[9] | Mishra GA, Pimple SA, Shastri SS. An overview of prevention and early detection of cervical cancers. Vol. 32, Indian Journal of Medical and Paediatric Oncology. Wolters Kluwer -- Medknow Publications; 2011. p. 125–32. |
[10] | Safaeian M, Solomon D, Castle PE. Cervical Cancer Prevention-Cervical Screening: Science in Evolution. Vol. 34, Obstetrics and Gynecology Clinics of North America. Elsevier; 2007. p. 739–60. |
[11] | Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Heal [Internet]. 2016 Jul [cited 2019 Apr 30]; 4(7): e453–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27340003. |
[12] | Organization WH. Comprehensive cervical cancer prevention and control—a healthier future for girls and women: WHO guidance note. Geneva: WHO; 2013. WHO Recomm use HPV test Prim Screen also Recomm Prolong Screen interval to up to. 10. |
[13] | Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath JA, Chipato T, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG An Int J Obstet Gynaecol [Internet]. 2000 Jan 1 [cited 2018 Mar 20]; 107(1): 33–8. Available from: http://doi.wiley.com/10.1111/j.1471-0528.2000.tb11576.x. |
[14] | Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human Papillomavirus DNA Testing for Cervical Cancer Screening in Low-Resource Settings. JNCI J Natl Cancer Inst [Internet]. 2000 May 17 [cited 2018 Mar 20]; 92(10): 818–25. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/92.10.818. |
[15] | Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev [Internet]. 2000 Sep 1 [cited 2018 Mar 20]; 9(9): 945–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11008913. |
[16] | Poli UR, Bidinger PD, Gowrishankar S. Visual Inspection with Acetic Acid (VIA) Screening Program: 7 Years Experience in Early Detection of Cervical Cancer and Pre-Cancers in Rural South India. Indian J Community Med [Internet]. 2015 [cited 2018 Mar 20]; 40(3): 203–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26170547. |
[17] | WHO | Prevention of cervical cancer through screening using visual inspection with acetic acid (VIA) and treatment with cryotherapy. WHO [Internet]. 2014 [cited 2018 Mar 20]; Available from: http://www.who.int/reproductivehealth/publications/cancers/9789241503860/en/. |
[18] | WHO guidelines WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. [cited 2018 Feb 6]; Available from: http://apps.who.int/iris/bitstream/10665/94830/1/9789241548694_eng.pdf. |
[19] | Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al. Effectiveness of VIA, Pap, and HPV DNA Testing in a Cervical Cancer Screening Program in a Peri-Urban Community in Andhra Pradesh, India. Myer L, editor. PLoS One [Internet]. 2010 Oct 28 [cited 2018 Sep 26]; 5(10): e13711. Available from: http://dx.plos.org/10.1371/journal.pone.0013711. |
[20] | Viviano M, DeBeaudrap P, Tebeu P-M, Tsuala Fouogue J, Vassilakos P, Petignat P. A review of screening strategies for cervical cancer in human immunodeficiency virus-positive women in sub-Saharan Africa. Int J Womens Health [Internet]. 2017 Feb 2 [cited 2018 Sep 27];Volume 9: 69–79. Available from: https://4m.cn/5FfDj. |
[21] | Umulisa MC, Franceschi S, Baussano I, Tenet V, Uwimbabazi M, Rugwizangoga B, et al. Evaluation of human-papillomavirus testing and visual inspection for cervical cancer screening in Rwanda. BMC Womens Health [Internet]. 2018 Dec 24 [cited 2018 Sep 27]; 18(1): 59. Available from: https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-018-0549-5. |
[22] | Wittet, S and Goltz, S and Cody A. Progress in Cervical Cancer Prevention: The CCA Report Card 2015. |
[23] | World Health Organization. WHO guidelines for treatment of cervical intraepithelial neoplasia 2–3 and adenocarcinoma in situ. WHO Guidel [Internet]. 2014; 52 p. Available from: http://apps.who.int/iris/bitstream/10665/104174/1/9789241506779_eng.pdf?ua=1. |
[24] | Cancer Action C. Cervical Cancer Action Coalition | New Options for Cervical Cancer Screening and Treatment 2 inspection with acetic acid (VIA) for screening, and cryotherapy for treatment, with a focus on approaches appropriate for low-resource settings. Cervical screening and treatment: Still a priority in the age of vaccines. [cited 2018 Mar 20]; Available from: https://pdfs.semanticscholar.org/dbf2/3aab877662a8388bd15b4afc53cafb36ccb1.pdf. |
[25] | Castro, W and Gage, J and Gaffikin, L and Ferreccio, C and Sellors J. Effectiveness safety and acceptability of cryotherapy: a systematic literature review. Seattle Washingt Progr Appropr Technol Heal [PATH] Alliance Cerv Cancer Prev 2003 Jan. 2003. |
[26] | What is a Loop Electrosurgical Excision Procedure (LEEP)? [Internet]. [cited 2020 Oct 5]. Available from: https://www.plannedparenthood.org/learn/cancer/cervical-cancer/whats-leep. |
[27] | Cervical Cancer Prevention and Screening: Financial Issues [Internet]. [cited 2020 Oct 15]. Available from: https://4m.cn/RfcQW. |
[28] | What is GRADE? | BMJ Best Practice [Internet]. [cited 2020 Aug 22]. Available from: https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/. |
[29] | Mvundura M, Tsu V. Estimating the costs of cervical cancer screening in high-burden Sub-Saharan African countries. Int J Gynecol Obstet [Internet]. 2014 Aug [cited 2018 Sep 14]; 126(2): 151–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24792401. |
[30] | Campos NG, Jeronimo J, Tsu V, Castle PE, Mvundura M, Kim JJ. The cost-effectiveness of visual triage of human papillomavirus–positive women in three low- and middle-income countries. Cancer Epidemiol Biomarkers Prev. 2017 Oct 1; 26(10): 1500–10. |
[31] | Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. N Engl J Med [Internet]. 2005 Nov 17 [cited 2018 Sep 3]; 353(20): 2158–68. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMsa044278. |
[32] | Nelson S, Kim J, Wilson FA, Soliman AS, Ngoma T, Kahesa C, et al. Cost-Effectiveness of Screening and Treatment for Cervical Cancer in Tanzania: Implications for other Sub-Saharan African Countries. Value Heal Reg Issues [Internet]. 2016 Sep 1 [cited 2018 Sep 9]; 10: 1–6. Available from: https://www.sciencedirect.com/science/article/pii/S2212109916000108. |
[33] | Legood R, Gray AM, Mahé C, Wolstenholme J, Jayant K, Nene BM, et al. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected. Int J Cancer. 2005 Dec 20; 117(6): 981–7. |
[34] | Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine [Internet]. 2009 Oct 19 [cited 2019 Apr 16]; 27(44): 6196–202. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19698807. |
[35] | Zimmermann MR, Vodicka E, Babigumira JB, Okech T, Mugo N, Sakr S, et al. Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya. Cost Eff Resour Alloc [Internet]. 2017 [cited 2018 Mar 20]; 15: 13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28725164. |
[36] | Campos NG, Castle PE, Wright TC, Kim JJ, Kim JJ. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage. Int J cancer [Internet]. 2015 Nov 1 [cited 2018 Sep 27]; 137(9): 2208–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25943074. |
[37] | Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahé C, et al. Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries. N Engl J Med [Internet]. 2005 Nov 17 [cited 2020 May 3]; 353(20): 2158–68. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMsa044278. |
[38] | Shi J-F, Chen J-F, Canfell K, Feng X-X, Ma J-F, Zhang Y-Z, et al. Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Serv Res [Internet]. 2012; 12(1): 123. Available from: http://bmchealthservres.biomedcentral.com/articles/10.1186/1472-6963-12-123. |
[39] | Lince-Deroche N, Phiri J, Michelow P, Smith JS, Firnhaber C. Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa. PLoS One. 2015; 10(11). |
[40] | Mezei AK, Pedersen HN, Sy S, Regan C, Mitchell-Foster SM, Byamugisha J, et al. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: A cost-effectiveness analysis of the ASPIRE trial. BMJ Open. 2018 Jun 1; 8(6): e020484. |
[41] | Campos NG, Tsu V, Jeronimo J, Mvundura M, Lee K, Kim JJ. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. Int J Cancer. 2017 Mar 15; 140(6): 1293–305. |
[42] | Vodicka EL, Chung MH, Zimmermann MR, Kosgei RJ, Lee F, Mugo NR, et al. Estimating the costs of HIV clinic integrated versus non-integrated treatment of precancerous cervical lesions and costs of cervical cancer treatment in Kenya. PLoS One. 2019 Jun 1; 14(6). |
[43] | Marseille E, Dandona L, Marshall N, Gaist P, Bautista-Arredondo S, Rollins B, et al. HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res [Internet]. 2007 Jul 12 [cited 2019 May 27]; 7: 108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17626616. |
[44] | Galárraga O, Wamai RG, Sosa-Rubí SG, Mugo MG, Contreras-Loya D, Bautista-Arredondo S, et al. HIV prevention costs and their predictors: evidence from the ORPHEA Project in Kenya. Health Policy Plan [Internet]. 2017 Dec 1 [cited 2019 May 27]; 32(10): 1407–16. Available from: https://academic.oup.com/heapol/article/32/10/1407/4237470. |
[45] | Hewett PC, Nalubamba M, Bozzani F, Digitale J, Vu L, Yam E, et al. Randomized evaluation and cost-effectiveness of HIV and sexual and reproductive health service referral and linkage models in Zambia. BMC Public Health [Internet]. 2016; 16(1): 785. Available from: http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-016-3450-x. |
[46] | Olwanda E, Shen J, Kahn JG, Bryant-Comstock K, Huchko MJ. Comparison of patient flow and provider efficiency of two delivery strategies for HPV-based cervical cancer screening in Western Kenya: a time and motion study. Glob Health Action [Internet]. 2018 Jan 28 [cited 2018 Dec 17]; 11(1): 1451455. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29589991. |